TG Therapeutics continues strong execution with Briumvi, maintaining beat-and-raise performance and robust financials, including a new $100 million buyback program. However, high investor expectations ...

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at where TG Therapeutics, Inc. (NASDAQ:TGTX) stands against other best performing ...

Briumvi shows increasing revenues but faces decelerating growth, suggesting possible market saturation or increased competition. TG Therapeutics has a strong balance sheet but contends with high SG&A ...

TG Therapeutics (TGTX) posted a net profit margin of 13.3%, down from 27.6% a year ago, but remained profitable with strong momentum. Five-year average annual earnings growth reached 48.3%. The ...